Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey
Relief Fund, $50,000 to the American Red Cross
WOODCLIFF LAKE, N.J., Nov. 19, 2012
WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ --In conjunction with Eisai
Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc.,
announced today that it will be making a donation of $100,000 to the Hurricane
Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red
Cross in an effort to help provide relief to the many areas damaged by
(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )
"The devastation caused by Hurricane Sandy has affected so many people
throughout the East Coast, including many of our employees and their
relatives, friends and neighbors," said Lonnel Coats, President and CEO of
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd. "We hope these donations
will support efforts to help ease the burden and suffering for those whose
lives have been disrupted in very challenging ways."
Eisai USA Foundation Inc.
The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's
commitment to be a responsiblecorporate citizen and contribute to the good of
the society in which it does business. The Foundation focuses its charitable
giving in four areas: health-related initiatives for patients and caregivers,
disaster relief efforts, innovation in medical and pharmaceutical sciences,
and community activities in the areas where Eisai's U.S. employees live and
Eisai Inc. was established in 1995 and began marketing its first product in
the United States in 1997. Since that time, Eisai Inc. has rapidly grown to
become a fully integrated pharmaceutical business. Eisai's key areas of
commercial focus are neurology and oncology. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health
care (hhc) company that discovers, develops and markets products throughout
Eisai has a global product creation organization that includes U.S.-based R&D
facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as
well as manufacturing facilities in Maryland and North Carolina. The company's
areas of R&D focus include neuroscience; oncology; vascular, inflammatory and
immunological reaction; and antibody-based programs. For more information
about Eisai, please visit www.eisai.com/US.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
SOURCE Eisai Inc.
Contact: Media Inquiries - Lynn Kenney, Eisai Inc., +1-201-746-2294; Investor
Inquiries - Alex Scott, Eisai Inc., +1-201-746-2177
Press spacebar to pause and continue. Press esc to stop.